阅读说明：本技术 20-取代-5-o-碳霉胺糖基-泰乐内酯衍生物 (20-substituted-5-O-mycaminosyl-tylonolide derivatives ) 是由 不公告发明人 于 2019-09-30 设计创作，主要内容包括：本发明涉及新的大环内酯类衍生物,具体为含有喹啉基、吡啶基的20-1<I>H</I>-1,2,3-三氮唑-5-<I>O</I>-碳霉胺糖基泰乐内酯衍生物、其合成方法及该衍生物的兽用药用组合物及在动物疾病中的应用。所述衍生物通式如下,其在治疗动物蓝耳病毒感染、支原体感染或细菌感染等方面有很好的药物用途。其制备方法简单,条件温和,收率高。<Image he="165" wi="263" file="DEST_PATH_IMAGE001.GIF" imgContent="drawing" imgFormat="GIF" orientation="portrait" inline="no"></Image>(The present invention relates to a novel macrocyclic lactoneEster derivatives, specifically 20-1 containing quinolyl and pyridyl H -1,2, 3-triazole-5- O -mycaminosugatylactone derivatives, their synthesis and veterinary pharmaceutical compositions and their use in animal diseases. The derivative has the following general formula, and has good medicinal application in the aspects of treating animal blue ear virus infection, mycoplasma infection or bacterial infection and the like. The preparation method is simple, mild in condition and high in yield.)

1.20-quinolyl or pyridyl-1H-1, 2, 3-triazole-5-O-mycaminosyl-tylonolide derivative or salt thereof, which is characterized in that the structural general formula is as follows:

R₁selected from i or ii or iii or iv:

i is a straight chain alkyl group containing 1 to 6 carbon atoms; or a straight-chain alkyl group having 1 to 3 carbon atoms substituted with a saturated five-membered cycloalkyl group or a saturated six-membered cycloalkyl group;

ii is a saturated five-membered ring group or a saturated six-membered ring group;

iii is a mono-or poly-substituted phenyl group; or a mono-or polysubstituted benzyl radical, the substituents being selected from the group consisting of F, Cl, Br, dimethylamino or trifluoromethyl or a linear or branched alkyl radical having from 1 to 6 carbon atoms;

iv is selected from hydrogen;

R₂selected from quinolyl and pyridyl.

2. The 20-quinolyl or pyridyl-1H-1, 2, 3-triazole-5-O-mycaminosyl-tylonolide derivative or salt thereof as claimed in claim 1, wherein R is₂Is selected from

3. 20-quinolyl or pyrazinyl according to claim 2The pyridyl-1H-1, 2, 3-triazole-5-O-mycaminosyl-tylonolide derivative or salt thereof is characterized in that R₁Is a mono-substituted benzyl group, the substituents being selected from F, Cl or Br;

R₂is selected from

4. The 20-quinolyl or pyridyl-1H-1, 2, 3-triazole-5-O-mycaminosyl-tylonolide derivative or salt thereof according to claim 1, wherein one of the following compounds is selected:

5. the 20-quinolyl or pyridyl-1H-1, 2, 3-triazole-5-O-mycaminosyl-tylonolide derivative or salt thereof of claim 4, wherein the compound is selected from the group consisting of 2-4, 2-5:

6. the 20-quinolinyl or pyridinyl-1H-1, 2, 3-triazole-5-O-mycaminosyl-tylonolide derivative or salt thereof as claimed in any one of claims 1 to 5, wherein the salt forming acid is selected from baicalin, caffeic acid, shikimic acid, citric acid, lactic acid, citric acid or tartaric acid.

7. The pharmaceutical use of the 20-quinolyl or pyridyl-1H-1, 2, 3-triazole-5-O-mycaminosyl-tylonolide derivative or the salt thereof according to any one of claims 1 to 6, wherein the derivative or the salt thereof is used as an active ingredient for preparing a medicament for treating or preventing viral and bacterial infections of animals.

8. The pharmaceutical use of the 20-quinolyl or pyridyl-1H-1, 2, 3-triazole-5-O-mycaminosyl-tylonolide derivative or the salt thereof according to claim 7, wherein the derivative or the salt thereof is used for preparing a medicament for treating or preventing chicken arthritis and tenosynovitis; the compound is used for preparing a medicament for treating or preventing porcine reproductive and respiratory syndrome caused by the porcine reproductive and respiratory syndrome; the compound is used for preparing medicaments for treating or preventing the bovine respiratory diseases caused by pasteurella hemolyticus, pasteurella multocida and mycoplasma bovis; the preparation method is used for preparing the medicine for treating or preventing the bovine intestinal diseases caused by the Escherichia coli; for the preparation of a medicament for the treatment or prevention of mastitis in dairy cows caused by Staphylococcus aureus, Streptococcus uberis, Streptococcus agalactiae, Streptococcus dysgalactiae, Corynebacterium or enterococcus; is used for preparing medicaments for treating or preventing porcine respiratory diseases caused by actinobacillus pneumoniae, pasteurella multocida or mycoplasma.

9. The pharmaceutical use of the 20-quinolyl or pyridyl-1H-1, 2, 3-triazole-5-O-mycaminosyl-tylonolide derivative or the salt thereof according to claim 7 or 8, wherein the derivative or the salt thereof is prepared into injection, powder injection, tablet, granule, capsule, soluble powder or powder.

Technical Field

The invention relates to a novel 20-1H-1,2, 3-triazole-5-O-mycaminosugal tylonolide derivative containing quinolyl and pyridyl, a preparation method and application thereof, and belongs to the field of pharmaceutical chemistry.

Background

For a long time, the diseases caused by mycoplasma pneumonia, porcine reproductive and respiratory syndrome virus and other bacterial infections of livestock and poultry are most frequent, most popular and most difficult to purify, and are always considered to be one of important epidemic diseases causing great economic loss to the breeding industry. In recent years, the infection is often mixed with other pathogens, thereby causing great economic loss. The porcine respiratory complex disease is the result of the synergistic effect of mycoplasma hyopneumoniae with the environment and various pathogenic microorganisms. Porcine reproductive and respiratory syndrome is a disease caused by porcine reproductive and respiratory syndrome. The common mycoplasma gallisepticum includes mycoplasma gallisepticum and mycoplasma synoviae, and is also a disease which troubles the breeding industry and affects the production performance. Therefore, the development of chemical drugs with significant efficacy on mycoplasma and effective on the blue-ear virus is a problem which needs to be solved urgently by the breeding industry at present. Meanwhile, with the increasing clinical drug resistance of chemical drugs, the market demands the research and development of novel chemotherapeutic drugs.

Tylosin belongs to macrolide medicines and has antibacterial and mycoplasma resisting effects. Tylosin has become a drug for the treatment of gram-positive bacterial and mycoplasma infections in livestock and poultry. In order to further expand the antibacterial spectrum of tylosin compounds and improve the oral bioavailability, researchers have experimented with a large number of tylosin derived drugs and 15-ring macrolide veterinary drugs, in particular tylosin, acetylisovaleryltylosin, tilmicosin, tildipirosin, gamithromycin, tylosin and the like represented by the following formulas, respectively.

The antibiotics are used for treating bacterial and mycoplasma infections of livestock and poultry, and are the most important antibiotics commonly used by livestock and poultry at present. However, with the use of these antibiotics, the situation of resistance is becoming more severe, and therefore, the development of new antibiotics capable of resisting bacteria and mycoplasma infection is becoming more important.

5-O-mycaminosugatylactone (OMT) is a precursor of tylosin biosynthesis, and the absence of mycose residues in OMT is understood to open up an excellent method for placing amino acid or peptide residues in the gaps of the ribosomal steric structure from the action mechanism.

Tylonolide is one of OMT derivatives, which is approved as a new veterinary drug at present, but the gram-positive antibacterial activity against Staphylococcus aureus, Streptococcus agalactiae and the like is still unsatisfactory, and the continuous search for better compounds against gram-positive bacteria is a development direction. The documents DOI:10.1124/mol.106.026567 and DOI:10.1021/jm034233m report that the antibacterial activity of the compound introduced with quinoline structure is equivalent or improved compared with tylosin. Patent WO2014/187957A1 and document DOI 10.1038/ja.2017.61 report 5-O-mycaminosugatolactone derivatives partially introduced with quinoline groups and antibacterial activity on gram-positive or negative bacteria, drug-sensitive bacteria and drug-resistant strains, wherein compounds 2k (YT709) and 2f (YT650) show better antibacterial activity, MICs on drug-sensitive bacteria staphylococcus aureus are respectively less than or equal to 0.125 mu g/mL and 0.25 mu g/mL, and MICs on escherichia coli standard strains are respectively greater than 64 mu g/mL and 4 mu g/mL. However, the compounds with good antibacterial activity on mycoplasma, porcine reproductive and respiratory syndrome viruses and negative bacteria are not reported in the documents, the strain variety range used in the document DOI:10.1038/ja.2017.61 is narrow, and the activity on pasteurella, mycoplasma and porcine reproductive and respiratory syndrome viruses is not detected.

Therefore, the 5-O-mycaminosugatylactone is used as a raw material, the compound is structurally modified to prepare a series of compounds with new structures and excellent activities of resisting bacteria, mycoplasma and the blue ear virus, and the method has important significance for researching new broad-spectrum antibacterial, mycoplasma and blue ear virus resisting and drug-resistant antibiotics.

Disclosure of Invention

The invention aims to provide a series of 20-1H-1,2, 3-triazole-5-O-mycaminosugal tylonolide derivatives containing quinolyl and pyridyl with good antibacterial and antiviral activities.

In order to realize the purpose of the invention, the technical scheme is as follows:

the 20-1H-1,2, 3-triazole-5-O-mycaminosugal tylonolide derivative containing quinolyl and pyridyl has the following structural general formula:

including pharmaceutically acceptable salts, esters, prodrugs or solvate thereof.

R₁Selected from i or ii or iii or iv:

i is a straight chain alkyl group containing 1 to 12 carbon atoms; or a saturated or unsaturated five-membered or six-membered cycloalkyl group-substituted straight-chain alkyl group having 1 to 5 carbon atoms;

ii is a saturated or unsaturated five-membered cycloalkyl or six-membered cycloalkyl;

iii is a mono-or poly-substituted saturated or unsaturated five-or six-membered cycloalkyl radical, the substituents being selected from F, Cl, Br or trifluoromethyl, or a linear or branched alkyl radical of 1 to 6 carbon atoms;

iv is selected from hydrogen;

R₂selected from quinolyl and pyridyl.

Preferably: r₁Selected from i or ii or iii or iv:

i is a straight chain alkyl group containing 1 to 6 carbon atoms; or a straight-chain alkyl group having 1 to 3 carbon atoms substituted with a saturated five-membered cycloalkyl group or a saturated six-membered cycloalkyl group;

ii is a saturated five-membered ring group or a saturated six-membered ring group;

iii is a mono-or poly-substituted phenyl group; or a mono-or polysubstituted benzyl radical, the substituents being selected from F, Cl, Br, I or trifluoromethyl, or a linear or branched alkyl radical having from 1 to 6 carbon atoms;

iv is selected from hydrogen;

R₂selected from quinolyl and pyridyl. Preferably:

more preferably: r₁Is a mono-substituted benzyl group, the substituents are selected from F, Cl, Br, I,

R₂is selected from

The following specific compounds are preferred:

more preferred are the following specific compounds:

the preparation method of the compound provided by the invention is realized through the following reaction route:

dissolving OMT in an organic solvent, adding a compound of a general formula 1, and reacting under the catalysis of a reducing agent to obtain a white or yellow solid;

the reducing agent is one or two of formic acid, acetic acid, sodium triacetoxyborohydride, sodium borohydride or sodium cyanoborohydride;

the organic solvent is one or two of ethyl acetate, butyl acetate, amyl acetate, dichloromethane, 1, 2-dichloroethane, methanol, ethanol, acetonitrile, acetone, methyl formate and ethyl formate.

OMT (organic solvent) is shown in the general formula 1, wherein the molar ratio of catalyst feeding is 1: 1-4.

Wherein the compound of formula 1 is according to DOI: 10.1021/acs, molpharmaceut.7b00832, the raw materials are substituted aldehyde compound, propargylamine and 3-substituted-quinoline, which are commercially available, and OMT is obtained by hydrolyzing mycose and allose in acid solution with tylosin.

The synthetic methods of the present invention include, but are not limited to, the addition or removal of an appropriate protecting group before or after the above steps to obtain the compounds of the present invention.

The salt-forming acid selected by the invention is organic acid or inorganic acid, and the organic acid comprises baicalin, caffeic acid, shikimic acid, citric acid, lactic acid, citric acid, tartaric acid and the like.

The compounds of the invention are useful for treating or preventing diseases in animals caused by infection, the bacteria or mycoplasma or viruses causing the infection including staphylococcus, streptococcus, lactobacillus, enterococcus, enterobacter, erwinia, pasteurella, actinobacillus, bifidobacterium, peptostreptococcus, rickettsia, treponema, legionella, campylobacter, brucella, mycoplasma, ureaplasma, escherichia, listeria, bacillus, clostridium, DNA viruses, RNA viruses.

Specifically, the compounds of the present invention can treat livestock and poultry diseases caused by staphylococcus, streptococcus, lactobacillus acidophilus, mycobacterium tuberculosis, pasteurella, enterococcus faecalis, enterococcus faecium, streptococcus uberis, streptococcus agalactiae, streptococcus dysgalactiae, klebsiella pneumoniae, streptococcus gallic acid, escherichia coli, pseudomonas aeruginosa, mannheimia, mycoplasma pneumoniae, mycoplasma gallisepticum, mycoplasma synoviae, blue-ear virus, influenza virus, and the like.

The bacterial or viral infections and diseases caused by said infections include, but are not limited to, the following: respiratory infections caused by streptococcus pneumoniae, haemophilus influenzae, staphylococcus aureus, streptococcus digestions, pseudomonas, mycoplasma pneumoniae, chlamydia pneumoniae. Soft tissue infection, abscess and postpartum high fever caused by staphylococcus aureus, staphylococcus haemolyticus, streptococcus agalactiae and the like. Urinary tract infections caused by staphylococci and enterococci. Toxic diseases caused by infection with staphylococcus aureus and streptococcus. Ulcers caused by helicobacter pylori.

Useful for treating or preventing such disorders in animals include, but are not limited to, the following: arthritis and tenosynovitis of chicken caused by mycoplasma synoviae. Porcine reproductive and respiratory syndrome (PPRS) caused by the porcine reproductive and respiratory syndrome. Bovine respiratory diseases caused by pasteurella haemolytica, pasteurella multocida, mycoplasma bovis. Bovine intestinal disease caused by E.coli. Mastitis in dairy cows is caused by Staphylococcus aureus, Streptococcus uberis, Streptococcus agalactiae, Streptococcus dysgalactiae, Corynebacterium or enterococcus. Porcine respiratory disease caused by actinobacillus pneumoniae, pasteurella multocida, or mycoplasma. The invention is especially effective to respiratory diseases of farm animals such as pigs, cattle and chickens.

The amount of the present invention to be expressed in terms of treating or preventing a bacterial or viral infection is expressed as a "therapeutically effective amount" and may vary depending on the size, body weight, specific surface area of the animal or the compound of the present invention.

The effective amount of the present invention may be increased or decreased in proportion to the degree of urgency of the disease.

The use of the compounds of the invention and pharmaceutically acceptable salts, esters, prodrugs or solvate thereof: the active ingredient is combined with at least one pharmaceutically acceptable carrier, adjuvant or diluent to prepare a pharmaceutical composition or a veterinary drug composition, and the pharmaceutical composition or the veterinary drug composition is used for producing biological medical products and treating diseases such as respiratory infectious diseases, arthritis, mastitis and the like of livestock and poultry.

By "veterinary composition" is meant a composition comprising said compounds in a proportion varying from 0.1 to 99.5%.

An "acceptable carrier" is an acceptable ingredient disclosed in the pharmaceutical field, and is a solid or liquid filler, excipient, solvent, diluent, etc., which helps transport, absorption and distribution of the drug to be tested in the body, and must not be harmful to the patient.

The preparation of the invention includes but is not limited to final sterilized injection, non-final sterilized injection, powder injection, tablet, granule, capsule, soluble powder and powder.

The term "animal" as used herein generally includes, but is not limited to, humans, cattle, pigs, chickens, ducks, goats, sheep, dogs, cats, rats, mice, rabbits, ducks, etc., especially farm animals cattle, pigs, chickens, ducks.

The invention has the innovation points and advantages that: c-20 position of OMT is modified, 20-1H-1,2, 3-triazole-5-O-mycaminosugatalactone derivatives containing quinolyl and pyridyl are designed and synthesized, and unified antibacterial activity evaluation is carried out on the derivatives, wherein the evaluation includes gram-positive and gram-negative bacteria, drug-resistant strains and mycoplasma. The results show that: the series of compounds of the invention have excellent inhibitory activity on staphylococcus aureus, escherichia coli, drug-resistant streptococcus agalactiae, mycoplasma hyopneumoniae and porcine reproductive and respiratory syndrome virus (see tables 1-4). In particular compounds 2-4, 2-5. The inhibitory activity of the 2-4, 2-5 compounds against gram-positive and gram-negative bacteria was much improved compared to the control. The 2-4, 2-5 compounds show excellent inhibitory activity against mycoplasma and porcine reproductive and respiratory syndrome viruses. Compared with 2k and 2f (DOI:10.1038/ja.2017.61), the compound provided by the invention has remarkably improved activity on gram-positive bacteria and gram-negative bacteria, and has extremely high activity on clinically-isolated drug-resistant strains such as staphylococcus aureus and streptococcus, mycoplasma, blue-ear virus and the like, so that the superiority of the compound provided by the invention is shown. The synthesis method is simple, has high yield of over 75 percent, and is beneficial to the practical production and implementation conversion. Opens up a new way for researching new antibacterial broad-spectrum drug-resistant antibiotics and has important significance for developing self-owned intellectual property drugs.

Detailed Description

The present invention will be further described with reference to the following examples.